Drug regulations tied to fewer prescriptions of effective gout drug

April 9, 2015, Springer

Well intentioned, but costly and potentially problematic. That's how researchers describe the end result of a decision by the Food and Drug Administration (FDA) to regulate colchicine, a drug used to treat gout, among other ailments. Fewer patients are actually now taking it, and it has come at a cost to their wallets, says study leader Aaron Kesselheim of Brigham and Women's Hospital and the Harvard Medical School in the US. The findings appear in the Journal of General Internal Medicine.

Colchicine had been sold at low cost for many years in the US. It is widely used to treat gout, and is the primary treatment for a rare inflammatory disease called familial Mediterranean fever. Its availability on the US market predated the FDA's regulatory authority to ensure the safety and effective use of prescription drugs, and numerous manufacturers made the drug, selling it for about $0.09 per pill.

In 2007, with the FDA's encouragement, one of these manufacturers conducted a small clinical trial demonstrating the safety and efficacy of a short course of the drug in managing acute flares of gout. The FDA approved this manufacturer's version, granting sole market rights and ordering all unapproved versions off the market by January 2011. Exclusive rights for at least seven years were also granted for its use to treat familial Mediterranean fever, although no new studies were done on its effectiveness to treat this disease. The manufacturer of the new version, called Colcrys, sold the drug for about $5.00 per pill.

To gauge the impact of these market changes, Kesselheim and his colleagues conducted a retrospective cohort study of close to 217,000 commercially insured patients. Between 2009 and 2012, these patients were all newly diagnosed with either gout or familial Mediterranean fever.

They found that the odds of a familial Mediterranean fever patient being prescribed colchicine within 30 days of receiving such a diagnosis dropped by 7.6 percent per month after the regulations were put in place, while the odds for gout sufferers dropped by 0.5 percent per month. They also found that average patients' monthly total prescription bills rose from $418 to $651.

One of the FDA's justifications for Colcrys' approval was new warnings in Colcrys' label about the potentially lethal risks of co-prescribing colchicine with the antibiotic clarithromycin. But Kesselheim and his colleagues found no change in the rates of co-prescriptions of these two drugs, or co-prescription of colchicine with the transplant rejection medication cyclosporine, another potentially deadly combination.

Kesselheim and his team say that although the FDA's attempts to strengthen its regulatory oversight related to unapproved drugs are laudable, it has come at a price to those who need colchicine. "The way this case was handled has led to a potentially useful , colchicine, being prescribed to fewer patients, while there have also been substantial cost increases for those who do use it and no evidence of reductions in unsafe co-prescriptions," says Kesselheim, in summarizing the findings.

Explore further: Anti-gout medication colchicine helps patients with recurrent pericarditis

Related Stories

Anti-gout medication colchicine helps patients with recurrent pericarditis

March 31, 2014
A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's ...

Medication shows mixed results in reducing complications from cardiac surgery

August 31, 2014
Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase ...

Watchdog group seeks FDA ban of antifungal tablets

February 24, 2015
(AP)—A consumer safety group is calling on the Food and Drug Administration to pull certain antifungal tablets off the market, saying there are safer medicines that do not carry risks of liver damage.

US prices soaring for some generic drugs

November 13, 2014
(HealthDay)—Market forces are dramatically driving up the cost of some generic drugs, prompting U.S. investigations into the pricing of what should be cheap alternatives to brand-name medications.

ESC: Colchicine effective for acute pericarditis

September 4, 2013
(HealthDay)—Colchicine is more effective than placebo in reducing the risk of incessant or recurrent pericarditis in patients with acute pericarditis, according to a study published online Sept. 1 in the New England Journal ...

Recommended for you

Doctors prescribe opioids at high rates to those at increased overdose risk

April 24, 2018
The number of first-time prescriptions for opioid drugs has not risen since about 2010, according to UCLA researchers. However, patients taking a class of drug known to increase the risk for overdoses were likelier to receive ...

Study: Ibuprofen, acetaminophen more effective than opioids in treating dental pain

April 17, 2018
Opioids are not among the most effective—or longest lasting—options available for relief from acute dental pain, a new examination of the results from more than 460 published studies has found.

Text messaging tool may help fight opioid epidemic

April 17, 2018
A new automated text messaging service may curb opioid abuse and reduce the likelihood of relapse while also decreasing treatment costs, according to researchers at Washington University School of Medicine and Epharmix, a ...

Marijuana-based drug gets positive review from US agency

April 17, 2018
A closely watched medicine made from the marijuana plant reduces seizures in children with severe forms of epilepsy and warrants approval in the United States, health officials said Tuesday.

Post-surgical opioids can, paradoxically, lead to chronic pain

April 16, 2018
Giving opioids to animals to quell pain after surgery prolongs pain for more than three weeks and primes specialized immune cells in the spinal cord to be more reactive to pain, according to a new study by the University ...

Animal study suggests common diabetes drug may also help with nicotine withdrawal

April 5, 2018
In a mouse study, a drug that has helped millions of people around the world manage their diabetes might also help people ready to kick their nicotine habits.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.